CoChat

Frontotemporal degeneration, the next therapeutic frontier: Molecules and animal models for frontotemporal degeneration drug development

Open access
Boxer, Adam L., Gold, Michael, Huey, Edward, Gao, Fen‐Biao, Burton, Edward A., Chow, Tiffany, Kao, Aimee, Leavitt, Blair R., Lamb, Bruce, Grether, Megan, Knopman, David, Cairns, Nigel J., Mackenzie, Ian R., Mitic, Laura, Roberson, Erik D., Van Kammen, Daniel, Cantillon, Marc, Zahs, Kathleen, Salloway, Stephen, Morris, John, Tong, Gary, Feldman, Howard, Fillit, Howard, Dickinson, Susan, Khachaturian, Zaven, Sutherland, Margaret, Farese, Robert, Miller, Bruce L., Cummings, Jeffrey · 2013 · Alzheimer's & Dementia
Cited by 80

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Abstract

Frontotemporal degeneration (FTD) is a common cause of dementia for which there are currently no approved therapies. Over the past decade, there has been an explosion of knowledge about the biology and clinical features of FTD that has identified a number of promising therapeutic targets as well as animal models in which to develop drugs. The close association of some forms of FTD with neuropathological accumulation of tau protein or increased neuroinflammation due to progranulin protein deficiency suggests that a drug's success in treating FTD may predict efficacy in more common diseases such as Alzheimer's disease. A variety of regulatory incentives, clinical features of FTD such as rapid disease progression, and relatively pure molecular pathology suggest that there are advantages to developing drugs for FTD as compared with other more common neurodegenerative diseases such as Alzheimer's disease. In March 2011, the Frontotemporal Degeneration Treatment Study Group sponsored a conference entitled “FTD, the Next Therapeutic Frontier,” which focused on preclinical aspects of FTD drug development. The goal of the meeting was to promote collaborations between academic researchers and biotechnology and pharmaceutical researchers to accelerate the development of new treatments for FTD. Here we report the key findings from the conference, including the rationale for FTD drug development; epidemiological, genetic, and neuropathological features of FTD; FTD animal models and how best to use them; and examples of successful drug development collaborations in other neurodegenerative diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jalz.2012.03.002

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 27 references

Cited by

See all 80

Metadata

Authors
Boxer, A. L., Gold, M., Huey, E., Gao, F., Burton, E. A., Chow, T., Kao, A., Leavitt, B. R., Lamb, B., Grether, M., Knopman, D., Cairns, N. J., Mackenzie, I. R., Mitic, L., Roberson, E. D., Van Kammen, D., Cantillon, M., Zahs, K., Salloway, S., Morris, J., Tong, G., Feldman, H., Fillit, H., Dickinson, S., Khachaturian, Z., Sutherland, M., Farese, R., Miller, B. L., & Cummings, J.
Venue
Alzheimer's & Dementia
Publisher
Wiley
Published
2012-10-08
Volume
9
Issue
2
Pages
176-188
ISSN
  • 1552-5260 (ISSN-L)
  • 1552-5279
OpenAlex
W2023590402
Cited by
80
References
27
FWCI
5.09
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Frontotemporal degeneration, the next therapeutic frontier: Molecules and animal models for frontotemporal degeneration drug development. https://app.cochat.ai/papers/10.1016/j.jalz.2012.03.002
The paper
Boxer, A. L., Gold, M., Huey, E., Gao, F., Burton, E. A., Chow, T., Kao, A., Leavitt, B. R., Lamb, B., Grether, M., Knopman, D., Cairns, N. J., Mackenzie, I. R., Mitic, L., Roberson, E. D., Van Kammen, D., Cantillon, M., Zahs, K., Salloway, S., . . . Cummings, J. (2013). Frontotemporal degeneration, the next therapeutic frontier: Molecules and animal models for frontotemporal degeneration drug development. Alzheimer's & Dementia. https://doi.org/10.1016/j.jalz.2012.03.002

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.